POLQ and leukemia: In addition, the study showed that inhibitors of oncogenic tyrosine kinases (OTK) or DNA–protein crosslink (dpc)-inducing drugs, such as etoposide, enhanced the anti-leukemia effects of POLQ inhibitors both in vitro and in vivo [18].